FDA Grants Orphan Drug Status to Zydus Lifesciences’ ZYIL1 for Treating Cryopyrin-Associated Periodic Syndrome
Zydus Lifesciences has announced that its drug, ZYIL1, has received orphan drug designation (ODD) from the United States Food and Drug Administration (US FDA) for the treatment of Cryopyrin Associated ...